IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

X ASTRAZENECA AB. :

Plaintiff,

v. : C.A. No. 14-696-GMS

MYLAN PHARMACEUTICALS, INC.,

:

Defendant.

: X

<u>AMENDED</u> SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA)

Plaintiffs hereby provide the information below with respect to the deadlines set forth in

21 U.S.C. § 355(j):

Date Patentee(s) Received Notice: No earlier than April 30, 2014

Date of Expiration of Patent: 7,951,400 (November 30, 2028)

RE44,186 (July 31, 2023) 8,628,799 (July 13, 2025)

Thirty Month Stay Deadline¹: No earlier than January 31, 2017

DATED: September 23, 2014 MCCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Michael P. Kelly (#2295) Daniel M. Silver (#4758)

Renaissance Centre

405 N. King Street, 8th Floor Wilmington, Delaware 19801

(302) 984-6300

mkelly@mccarter.com dsilver@mccarter.com

ME1 18887455v.1

_

¹ The stay preventing approval of the proposed generic products expires no earlier than January 31, 2017 (seven and one-half years from the new chemical entity approval on July 31, 2009). *See* 21 U.S.C. § 355(j)(5)(F)(ii).

Charles E. Lipsey
Finnegan, Henderson, Farabow, Garrett &
Dunner, L.L.P.
11955 Freedom Drive
Reston, VA 20190
(571) 203-2700
(202) 208-4400 (fax)
Charles.Lipsey@finnegan.com

James B. Monroe
Robert F. Shaffer
Maximilienne Bishop
Finnegan, Henderson, Farabow, Garrett &
Dunner, L.L.P.
901 New York Ave., N.W.
Washington, D.C. 20001
(202) 408-4000
(202) 408-4400 (fax)
James.Monroe@finnegan.com
Robert.Shaffer@finnegan.com
Max.Bishop@finnegan.com

Attorneys for Plaintiff AstraZeneca AB